Background: Due to decreasing cost, and increasing speed and precision, genomic sequencing in research is resulting in the generation of vast amounts of genetic data. The question of how to manage that information has been an area of significant debate. In particular, there has been much discussion around the issue of 'secondary findings' (SF)-findings unrelated to the research that have diagnostic significance.
Introduction
Recent advances in genome sequencing (GS)-both in decreased cost, increased speed and enhanced methods for analysis-have resulted in the newly widespread use of the technology in the clinic and in research. When traditional genetic tests (such as single gene or targeted panel testing for clinically significant variants) fail to provide a genetic explanation for patients or families with a suspected inherited disease, whole-exome and whole-GS are now feasible. These tests (collectively, GS)-wherein the genome, or the protein-coding parts of the genome, is sequenced in its entirety-are now widely available to answer a range of clinical or research questions, and might completely replace panel tests (a list of clinical targets used for diagnosis of genetic disease) in the foreseeable future.
The current use of GS in large-scale clinicalresearch projects, such as NHS England's 100 000 Genomes Project (100KGP; genomicsengland.co. uk), is resulting in the generation of vast amounts of genetic data. The question of how to manage findings from this data has become an area of significant interest and debate. In particular, there has been much debate around the issue of 'secondary findings' (SF)-findings beyond the aims of the study that have clinical significance to participants. Such results are becoming a more frequent issue in the era of genomic medicine; with each human genome expected to contain around 100 harmful variants, SF are not exceptional, but inevitable. These findings have the potential to improve health outcomes, but provide novel challenges for investigators responsible for studies.
This review aims to summarize the current debate around SF in clinical genomics research, and explores the potential challenges to investigators and healthcare professionals, while highlighting the areas of disagreement-between stakeholders, policies and the actual practices of projects currently underway.
Methods
A systematic search of PubMed, Web of Science, SCOPUS, MEDLINE, PsychINFO and Philosopher's Index was conducting using the search terms 'incidental findings', 'SF', 'additional findings' (AF) and terms for 'clinical sequencing' ('genetic sequencing', 'genomic sequencing', 'GS' and 'exome sequencing'). Articles were excluded if they focused on non-human aspects, did not discuss GS or if they included no (or only superficial) discussion of the concept of SF. Publications were included if they presented detailed or insightful discussions or data pertaining to SF in both clinical and research contexts, as they both present concepts relevant to clinical research. Papers focusing on direct-to-consumer or commercial context were excluded. Initial searching and screening was followed by reference scanning and 'snowballing', where the bibliographies of included papers were searched by hand, to find additional articles that are relevant to the review. In an effort to capture literature not necessarily published in an academic journal, additional searches were conducted outside these databases, including governmental reports, grey literature sites and the websites of key organizations.
Background 'SF' in genomics
Despite a seemingly recent interest in the subject, SF are not new to genetics, or even medicine at large. The issue of SF in imaging diagnostic tests is well described. 1, 2 Ranging from X-rays to magnetic resonance imaging (MRI), it is possible that imaging for one diagnostic purpose could reveal a previously unknown abnormality. In radiology, such findings would likely lead to pathological analysis of the anomaly-this often leads to questions as to whether such findings are subclinical, that is, if they had remained undetected there would be no clinical significance, but now they have to be investigated.
However, it also has the benefit of initiating treatment pre-symptomatically; but that risks causing psychological harm if a false positive is returned. 3 It is also possible that SF practices could increase the number of tests and investigations that a patient undergoes, adding to their time as a patient, and financial burdens however costs are met. As imaging technologies improve, the incidence of SF has increased.
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The same phenomenon has been observed in 'clinical genetics'-as the capabilities of these technologies increase, so does the incidence of SF. Early forms of genome-wide testing, such as karyotypes and chromosomal microarrays, have welldocumented cases of SF. [4] [5] [6] Such technologies detect a wide spectrum of variation, ranging from gene deletions to chromosome abnormalities. Some of these will be 'off-target'; like an X-ray or MRI, the technology does not discriminate between the specific point of interest and other data 'in the same picture'. Some of these additional sequence data might impact medical management; opportunistic detection of a variant could lead to better clinical outcomes (by guiding treatment, predicting response to specific drugs and leading to increased screening), or informed choices (such as in reproductive health). Some findings, however, may point to predispositions for which there are no interventions available-utility (if any) is limited to behavioural changes and life planning. Other findings will be benign, and if it were not for the chance discovery they would unlikely ever be known in the person's phenotype. Today, GS is replacing single gene approaches, allowing for the nearly 20 000 genes in the human genome to be sequenced simultaneously; an efficient strategy when looking to discover the cause of conditions for which pathogenic variants in many different genes can be causative. These technologies provide very fine resolution-allowing for potentially informative single base pair variants to be detected, including those unrelated to the primary condition. In fact, a recent study estimated that 1-2% of individuals who undergo GS will have an SF that is life-threatening and treatable. 7 Despite the common use of radiology by professionals to help describe SF in genomics, the analogy to imaging requires careful scrutiny. 3 Interpreting and managing genomic SF is complicated by our limited knowledge of the effect of individual variants, our inability to detect clinical symptoms for variants that are only predictive or conditions that are late-onset, the range of possible types of findings (e.g. clinically relevant, pharmacogenetic, reproductive or carrier status), and implications for relatives. 3, 8 Detecting a lesion on an MRI may be further investigated (if at all) for its genetic implications. Such a strategy could yield targeted genetic variants that might be shared within families, raising a unique set of practical and ethical issues. 9 The idea of genome-wide screening, however, makes the clinical strategy towards shared aetiologies more complex-where familial implications are inherent in all findings. When sequencing is designed to identify a wide range of variants, it becomes difficult to dismiss SFs as 'incidental'; that is, the targets are intentionally multiple. The dynamic nature of our knowledge of genetic variation also raises questions as to whether we should re-contact individuals in light of new evidence and how it is to be managed through clinical relationships and consent protocols. Furthermore, unlike in diagnostic imaging, many SF in genomics have to be actively sought; 10 the process of searching for, and analysing, these variants amongst the other thousands generated during GS is opportunistic-this 'secondary' intention has significant clinical implications, and therefore has become preferred, by many, to the idea of 'incidental'.
To disclose or not to disclose?
The most commonly cited argument against the disclosure of SF is that, in the absence of clinical utility, or even in cases where knowledge of a predisposition might allow for behaviour modification to minimize risk, it is possible for findings to cause anxiety and psychological harm. [11] [12] [13] [14] Similarly, some commentators raise the potential for harm by overloading participants with information, some of which might be unactionable. 13, 15, 16 Furthermore, all clinical data risks discrimination or stigmatization. 11, 17 These harms are not limited to the individual subjected to GS, as SF could have implications for family members. 15, 18, 19 Other arguments against SF disclosure largely revolve around feasibility: our developing knowledge around the utility of SF, lack of disease-specific expertise, and justice issues around the added burden on resources and research infrastructure. 12, 13, 15, 20 While the arguments for non-disclosure are diverse, support for disclosure of SF in GS has been framed as primarily the promotion of patient wellbeing. SF with confirmed clinical utility have the potential to inform treatment, provide patient choice or aid in disease prevention. [13] [14] [15] [18] [19] [20] [21] [22] [23] [24] [25] [26] Furthermore, this benefit potentially extends to members of the patient's family. 19 In a systematic review of ethical arguments around SF disclosure, Christenhusz et al. 27 found beneficence to be a strong guide for disclosure. Accordingly, Lohn et al. 28 verified that many authors have concluded that the benefits of disclosure outweigh the risks, and that full non-disclosure is ethically indefensible. One might think that withholding findings (although that says nothing about the nature of the information withheld), particularly when they improve health outcomes or enable better choices, requires a strong ethical justification. While a lack of proper clinical relationship might justify reluctance to disclose the findings, inconvenience or economic limitations seem less compelling. However, others acknowledge that complete disclosure is impractical given the limited knowledge about many variants. Thus, the two extreme positions of full disclosure or complete non-disclosure are seldom supported in practice. 12 Many of the aforementioned arguments opposing disclosure more accurately reflect support for very restricted disclosure, and arguments supporting return of SF more accurately reflect support of a wider qualified disclosure policy-one which respects participant autonomy. Where consensus, if any, will sit between these lesser extremes is yet to be seen.
Guidelines and recommendations
In November 2016, the American College of Medical Genetics and Genomics (ACMG) updated their widely discussed guidelines on SF in clinical GS. 29 In this update, they added 4 new members to a list of now 59 genes in which they recommend active screening and reporting to participants. This 'minimum gene list' includes genes in which pathogenic variants could imply risk of potentially life-threatening disease (a predisposition), where intervention is available, and in which a long asymptomatic phase may conceal disease expression. This builds on the original ACMG policy statement that argued that there is an obligation to seek and report variants of known (or in some cases expected) pathogenicity in the listed genes, and to interpret them in the context of the patient's personal and family history. 30 The genes on the list are, for the most part, genes in which there are variants known to be associated with cancer syndromes and inherited cardiac conditions. These include adultonset disorders, and the ACMG recommends that reporting SF not be limited by age-they argue that findings in children could benefit adult family members. While the initial set of guidelines recommended that SF were to be reported 'without reference to patient preferences', 30 subsequent updates allow patients to opt out of the analysis of all genes on the ACMG list due to criticism from the wider genetics community and a survey of their own members. The ACMG affirmed the importance of informed consent, and the need for a detailed discussion around the possibility of SF, as well as the consequences of opting out of notification. 31 Like the ACMG, many other organizations and groups have published recommendations around SF in GS, which have been comprehensively outlined in previous reviews. 8, 32 For the most part, guidelines differed from the ACMG in their stance on opportunistic screening of even life-threatening medically actionable conditions. Illustrative guidelines from the European Society for Human Genetics (ESHG) 17 and the Canadian College of Medical Genetics (CCMG) 33 recommended a much more cautious approach to SF, acknowledging the current lack of empiric knowledge on their utility (Table 1) . Both groups advocate for a targeted approach to analysis of GS, thus avoiding SF, such as by using selective filtering to limit the search space to genes relevant to the primary condition (thus minimizing chances of discovering something secondary). They acknowledge that, while not endorsed, some laboratories might choose to offer screening of minimum gene lists, and provide guidance on the process (i.e. informed consent and ability to opt out, as discussed above). In contrast to the guidelines in Table 1 , joint guidelines from the UK Medical Research Council and the Wellcome Trust, 34 as well as the report from the Presidential Commission on Bioethical Issues, 35 both provide much less instruction. Both documents stress the importance of investigators having a clear protocol in place on screening for and returning SF; however, neither advocates a specific policy. This serves to allow diversity across research programmes, while ensuring actions taken can be sensitive to context, which we explore next.
The research-clinical divide
The discussion around returning SF in 'research' is further complicated by the fact that the distinction between clinical and research domains has become blurred as GS is translated into clinical practice. 36 Current sequencing projects, such as the 100KGP, are operating at the interface of these domains. While under a research protocol, participants are recruited into these studies in the clinic, often by a clinician with whom they have had contact in a healthcare-providing capacity. Clinician-researchers must ensure that clinical standards of ethics continue, 37 which becomes an issue in pure research contexts where the same standards of care do not normally exist. However, Berkman et al. 38 argue that this convergence is inevitable and understandable in a translational field, and the collapse of this distinction is the very reason for the lack of consensus around SF. Accommodating clinical obligations serves to expand the 'ethical duties' of researchers, especially at times when technologies are uniquely available in a research context, as with genomics today. Hallowell et al. 13 noted, however, that differentiating between these two sets of activities is crucial as those involved have different 'primary' responsibilities: either based in clinical or research interests. In the case of the researcher, it is to advance science, and in the case of the clinician, it is a duty to their patient. However, Wolf 39 cautions against making this distinction-a continuum between research and clinic has been embraced through dual roles of clinician-researchers, and greater use of multidisciplinary collaborations, thus progress around SF requires 'recognizing that the debate is fundamentally about the translational process'. As a consequence of the blurred boundary between the clinic and research, many of the [12] [13] [14] [15] 23 This socalled 'therapeutic misconception' might lead them to take part in research. It also places burdens (both financial and professional) on researchers to deal with SF appropriately in every relevant case of research: protocols now have to specify whether there are resources and clinical follow-up to get a clear, beneficial message to the participant-including the counselling that accompanies disclosure and care in genetic medicine, additional staff and systems to handle clinically relevant data, and experts who are competent to interpret data in clinical circumstances. Some largescale GS studies include thousands of participants, many of whom could have health conditions potentially revealed by the study if SF are screened for systematically. Needing to have protocols for discovery, follow-up and notification procedures (and the resources to do so) on a systematic, rather than an ad hoc basis, may disqualify some studies from funding because of narrow conditions for successful calls, despite being scientifically sound. Some recommendations for dealing with SF that are research-specific have been put forward, often aiming to clarify responsibilities in the grey area between clinical duties and research ethics. They largely echo commonalities between clinical guidelines, such as the importance of informed consent and clearly explaining the possibility of SF to research participants, including which ones participants have the option of receiving, if any; and how to deal with actionable informationincluding access to counselling and privacy issues. 35, 40 However, some hold that there is no universal ethical obligation for researchers to actively search for SF, especially as limited research resources should be directed towards discovery. 40 In 2016, a National Institute of Health working group explored the issue of returning SF in a research context, concluding that some research studies should return SF, but obligatory return is not universally appropriate. 41 They outlined four factors that influence whether or not it is appropriate to return SF in a given study: nature of clinical relationship; nature of study; nature of study population and timeliness. Thus, although not always appropriate in a research context, they argue that any of the following are justification for seeking and returning SF: the investigator provides clinical care; the research question is clinical in nature; the study population is likely to find findings useful; or potential findings will arise while the participant is actively involved in the study. It is possible that, in cases where it is deemed appropriate, a separate source of funding or partnership (with the health system) could be established for the analysis of such findings, and their return to research participants, now entering a patient role.
Areas of agreement

Autonomy and informed consent
Initially an area of disagreement (before the ACMG updated their guidelines), the importance of participant autonomy in decision-making around SF is held to be universally important-by commentators and stakeholders alike. 42 Commentators widely hold that, regardless of the approach to disclosure taken, informed participant consent-and the resulting choices around SF disclosure-is central to the process. In a widely cited analysis of the ethical issues around SF, Wolf et al. 14 concluded that there is an obligation to explicitly address the possibility of SF in consent documents and in communication with participants at the outset. It is essential that participants are informed of the potential for SF, their implications, whether such findings will be returned, and asked which SF they would want returned (if any). This serves to maximize their autonomy, regardless of the range and nature of results on offer-respecting both their right to know and their right not to know. The possibility of SF, which are available for return, and how they will be disclosed, should all be discussed at the outset. This is directly reflected in the guidelines around SF: across the board, guidelines stressed the importance of discussing SF at the time of taking consent. Guidelines are also consistent in their allowing participants to opt out of the intentional analysis of a minimum list of genes. 17, 30, 33, 35, 36, 43, 44 However, though they agree, some commentators highlight challenges associated with respecting participants' autonomy. This might include when the patient has not been asked about such findings and a life-threatening SF is detected. 27 In certain circumstances, some argue that an SF that is grave and treatable might be cause to override a participant's decision not to receive SF. 23 Such findings have implications not only for the participant who made the decision, but also their blood relatives. 19 
Areas of controversy 'Actionability' and clinical utility
A recent systematic review of stakeholder views on SF in GS showed widespread agreement that 'actionable' results should be returned to participants. 42 This is consistent with the guidelines discussed, which encourage the return of SF (but not necessarily seeking them) if clinically relevant. However, stakeholders (ranging from GS participants to healthcare professionals) vary in their definition of actionability. While there is widespread agreement that SF for treatable life-threatening conditions should be returned (consistent with views taken by policy-makers reflected in the diverse range of guidelines), stakeholders variously included planning, lifestyle modifications and personal utility as aspects of SF 'actionability'.
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Even where there is agreement that variants in genes that indicate life-threatening treatable conditions should be returned, there is disagreement as to whether the variants themselves are sufficiently informative to justify their return. The original ACMG guidelines were criticized for lack of evidence on these matters: they cited no technical reports or systematic review. 45, 46 Critics argue that there is no evidence on the predictive value of testing or penetrance (proportion of individuals with a variant who express the associated characteristic) in an asymptomatic population: returning such variants in individuals without the associated presenting conditions is inconsistent with current practice, and therefore incongruous with current evidence. While the ACMG encouraged the collection of these data after the return of SF, 30 Burke et al. 45 stress the need for this evidence 'before' promoting active screening and disclosure processes.
Opportunistic screening
Rooted, in part, in this scepticism of the clinical utility of SF in GS, there are those who disagree with the ACMG recommendation of actively searching for these variants. This is clearly reflected in the other sets of guidelines, which do not endorse the intentional analysis of disease genes unrelated to the primary condition. 17, 33 In addition to a lack of known clinical utility, some highlighted the burden imposed on laboratories obligated to conduct extra analysis, questioning from where additional costs will be covered. 47 They also noted the further strain on resources caused by the additional counselling that will be required as a result of developing clinical care in respect to SF opportunity. Additional costs have the potential to widen the gap between individuals and institutions who can afford such care and those who cannot. While the ACMG guidelines have certainly influenced the design of many large-scale GS studies, other studies are taking different approaches to SF-ranging from avoidance of SF, to offering an even wider range than the ACMG recommendations. For example, in order to generate evidence on the benefits and risks of actively searching for and returning SF, the SickKids Genome Clinic 48 decided to screen 2000 genes for SF, based on the NIH Clinical Genomic Database of genetic disorders, 49 and will return adult-onset disorders regardless of age. At the other extreme, some studies have taken the decision to actively avoid the generation of SF altogether. As Wright et al. 50 advocates, interpretable data can be maximized, while minimizing unrelated findings, by targeting analysis to pertinent genes or using in silico gene panels. This approach-consistent with the guidelines from the ESHG and CCMG-has been taken by a range of studies. [51] [52] [53] In the UK, the 100KGP has taken a more intermediate approach, offering optional return of select 'AF' based on a shortened version of the ACMG list. At present, the list of AF only includes genes associated with cancer predisposition, such as BRCA1-participants with returned SF will receive counselling and be referred to the relevant clinical services. The 100KGP plans to update this list periodically and has established working groups to increase the number of genes based on new information and changing evidence. In addition to variants on the ACMG, the 100KGP offers the option of returning recessive and X-linked carrier status to couples and female participants, respectively.
SF in minors
The enrolment of children in research is controversial, and rather than introducing these complexities in this review, our comments are meant to be illustrative of the further debate needed in this area. Views towards returning SF in minors vary greatly ( Table 1 ). The original ACMG recommend the return of SF to children, including adult-onset conditions, regardless of age-on the basis that adult-onset findings in children could benefit family members, which could, in turn, benefit the child themself. Wolf et al. 46 argued that these guidelines depart from a well-established consensus on testing in minors, contradicting past recommendations from the ACMG. Returning adult-onset conditions to children of a mature standing-who are plausibly taking part in research-undermines their autonomy if they are not informed and given the choice. Those that are too young or immature are unlikely to be taking part in research without the 'best interest' proviso that the research directly benefits them; and, because of the condition for actionability, cannot express self-determination to clinical outcomes and therefore maintain an 'open future'. 45, 46 Others highlight that applying previous paediatric testing guidelines to SF is challenging, as the secondary nature of the findings means the child could be the only route by which these potentially life-saving findings are detected. Wilfond et al. 54 considers the concept of 'benefit to family'-where the harm threshold for the child is low, benefit to the family, and not just the child, should be considered. They hold that parentscarefully weighing the benefits and harms with a healthcare professional-should have greater discretion to obtain SF adult-onset conditions in their children.
Terminology
The lack of resolution in the debate around management of SF is reflected in the terminology itself: there was significant variation in the terminology applied to SF throughout the literature. While 'incidental' was the first name applied to these sorts of results, authors have pointed out problems associated with the term. 8, 55 In the case of GS, the use of the term 'incidental' is somewhat inaccurate-findings beyond those related to the primary condition are not completely incidental to the experimental strategy. The term 'incidental' is also problematic in that it could minimize the significance of the result, and is often used in cases where the findings are actively sought. 55 Christenhusz et al. 55 argued in support of the term 'secondary variants', which allows individuals to distinguish from those variants related to the primary condition without minimizing the potential weight of unrelated findings. This term is not without its own criticisms-some have argued that it has specific meaning in medicine, and might also minimize the importance of such findings relative to the primary findings. 56 In one update on the ACMG guidelines, 31 they endorsed the use of 'SF', citing the Presidential Commission for the Study of Bioethical Issues 35 as having made a case for the switch-referring to findings that fall inside the search protocol. The Presidential Commission, however, still employs the term 'incidental' to all findings that fall outside the research protocol. These 'incidental findings' include those that are 'anticipatable' (findings that are known to be associated with the procedure, but not actively sought) and 'unanticipatable' (findings that are not known to be associated with the procedure at the time it is conducted). This continued use of 'incidental' is problematic: although incidental to the research project (as used by the Presidential Commission Report 35 ), they are not incidental to the method employed. This distinction cannot be made apparent in the language itself: when using the phrase 'whole-GS' alongside these terms, although unrealistic, the analysis of the whole sequence is implicit-not a targeted analytical strategy. This unclear language creates an unnecessary dichotomy between non-primary findings that are sought and unsought, and minimizes the potential importance of unsought results. The language is confusing for professionals, let alone participants who are meant to provide informed consent.
Growing points
Inconsistent practices
One could postulate that the differences observed around SF management are a product of different medical systems, and cultures around healthcare and data sharing-especially differences between the USA and other countries. Klitzman et al. 57 acknowledged that the USA is much more litigious than other countries and that influences practices; and that resources might be more plentiful than in some countries-resulting in greater likelihood that a variant is actionable. Regardless of differences, it is critical that practices align more closely as large sequencing projects get underway and more individuals (with variable levels of training) become involved in clinical genomics research.
This misalignment in practices is mirrored in the complete lack of agreement on language around SF. 8, 55, 58 Although it has been argued that terminology can be adequately addressed with patients during the consent process, as all terminology requires explanation, 59 the reality of today's genomic medicine is that those seeking consent do not always have a sufficiently high level of genetic literacy to communicate these nuances. In an area where truly informed consent is already difficult to achieve, inconsistent and misleading terminology only further complicates matters. This can only serve to impede progress and collaboration, and threaten the quality of care provided the recipients of GS. Knoppers et al. 32 highlight the detrimental nature of these inconsistencies, calling for 'greater harmonization of practices and policies across countries' in order to better facilitate cross-border research collaboration. In order to truly harness the benefits of genomic medicine, policies need to be evidence-based. In order to generate this evidence, such as informative penetrance estimates, large data sets will be required. We therefore need to collate data across jurisdictions. Increasingly, data collections are international (along with research consortiums), with institutions joining and sharing resources to maximize 'Big Data'. The idea that, for such collaborations to work requires a standard approach is ever more commonplace. 60 
Innovation in genomics
In 'Imagined Futures', the Human Genome Organisation (HUGO) Committee on Ethics, Law and Society proposed a consolidated database of patients' genomes. 61 The 'trustworthy' health repository proposed would be populated by patients' genomes that could be quarried by their physicians via new 'genetic analysts', who, with counsellors, could transmit health information to patients. As well as comprehensively addressing the data handling issues of establishing and maintaining a biobank of immense size, HUGO also looked at expanding the clinical benefits into the research and public health domains. 62 This genomichealth framework HUGO described would be established as a public good-patients taking part in research would also be contributing to their own care through discovery. This shifts ideas of passive research subjects, to the active role of participants in data generation-and thereby creates value for them as partners in worthwhile initiatives, and as contributors to present and future community health. The patient-doctor relationship is preserved by information only being used for purposes that align clearly with their primary health interest and the collective health of the population. Such an innovation would be adaptive to our changing knowledge of genetics, including the regular reclassification of variants and discovery of new genedisease associations. A 'living' repository, actively supporting research, could adapt to the number and nature of diagnoses available to physicians as well. This would require reframing consent to allow researchers access to the data, and further permission for them to interrogate genomes for research purposes. Resulting information, for clinical purposes, would 'stay live'. This would allow physicians to access that growing data for their patients' diagnostics and treatments, for both primary and unrelated conditions. Accordingly, patients would agree to 'perpetual integration' in light of being part of new clinical information creation and its storage-patients' rights would be respected through opt-outs, anonymity (given the challenges of remaining so in terms of genomic forensics 63 ) or 'research use only' or 'clinical use only' status. This framework builds on the current debates about re-contact for SF (in research and clinical genetics), where it is widely considered to be ethically desirable, albeit unrealistic. 64 Despite widespread agreement on the difficulty of standardizing re-contact in practice, some research is being undertaken to explore its feasibility. 65, 66 Sequencing and interrogating each genome is a lengthy, costly and analytically complex task-there is a suggestion to do this just once in a lifetime and have that included in the repository. Re-contact is further complicated in a pure research setting, where sequencing and analytics are restricted by funding periods and contact time with participants. 42 A formal system for sequencing, storage and re-contact in light of SF, however, could maximize both clinical and research utility, potentially reducing health system burdens, satisfying concerned professionals, and maximizing patient benefit.
Areas timely for research
In order for consensus to be reached on the management of SF in GS, it is imperative that we collect data on actual returned SF. Many sources, including the ACMG guidelines themselves, 30 explain that data on the clinical utility of such findings will be paramount to informing their management. The need for such data can be illustrated by the incidence of the variants detected in research findings published to date-'pathogenic' variants are reported at a much higher rate than the population prevalence of the disease. The Oxford-based WGS500 study, 67 for instance, found seemingly pathogenic variants in genes known to cause arrhythmogenic right-ventricular cardiomyopathy (ARVC), in 2 individuals (out of 500 participants). A prevalence of 1:250 is dramatically higher than even the most liberal population estimate for ARVC (1:2000) . 68 This raises the question: while variants may be judged to be pathogenic in an individual with a related condition, do these variants (found as SF) have the same effect in patients who are unaffected? As randomized control trials are not possible with such small numbers, we must therefore employ creative methodologies to inform penetrance estimates of SF that will be disclosed.
69
A few studies have begun to generate this evidence, harnessing the power of large phenotyped databases or electronic medical records, to match phenotypic data with genome sequences. 70, 71 Two such studies reported that only 35% of the individuals with reportable variants from the ACMG list had the related clinical features or family history. However, while valuable in their provision of estimates, these studies do not utilize data ascertained for the purpose of diagnosing these conditions, and are unable to mirror the actual process of returning an SF and the resulting clinical assessment. Studies will need to be creative in their design and generate more evidence than is currently available-either by employing larger data sets or focusing on specific conditions or short gene lists. As large sequencing initiatives are underway, it is critical that they are harnessed to assess the clinical utility of these SF. If and once that case can be made, then it will be timely to look at participants' preferences to know SF, and how they handle that information (whether it is beneficial to them)-to date, such data are all hypothetical. 41 Finally, these data would have to come together in a research-orientated procedure for allying SF with research protocols and clinical outcomes. That is, it will be essential to look at the roles of scientists in analysing and transmitting clinically significant data to a participant, and enabling their transition to patient status.
Conclusion
'The power of genomics is that it provides a broad view of the landscape of heritability-it is wasteful to discard variants in all genes other than primary causative variant.' 72 How to harness that power, and whether or not we are ready to turn that into clinical benefit, is difficult to say. With full disclosure of SF being economically and logistically problematic, and complete non-disclosure being ethically knotty due to the potential benefits of some SF, a middle ground in SF management must be found. 28 First, consensus should be reached on which findings to seek and return, and when they should be sought. For these decisions to be made, better data on their utility and clinical impact on patients care are required. Next, work is needed to uncover the motivations for participants wanting SF returned, and the others who may not. In the context of clinical research, these motivations come in many forms, and may be comparable to the benefits or harms of knowing about SF in a clinical context. It would also be important to understand the reasons investigators give for wanting to return SF, while others do not. If it is concluded that genomic scientists are to become part of a clinical service by having a role in the routine return of SF, it would be urgent to bring them under a regulatory umbrella that accounts for 'clinical duties', including the provision of training and appropriate resources. More controversial would be re-situating the research-funding complex's primary interest to that of patient well-being. In the end, it is this challenge that may define the path of screening in clinical research.
Finally, the precise procedures for detecting and transmitting SF to participants need to be determined. The research context is not always a clinical one, and there will be many different conditions of participation, as a patient or as a volunteer. Importantly, scientists may not be subject to the same ethical, legal and professional duties as clinicians-these must be established before they assume a professional relationship (and therefore responsibility) to patients. Thus, for genomics to move from bench to bedside, we require innovative management strategies. This requires a nuanced (and educated) consent process, that possibly requires dynamic forms of consent, 73 which allows decisions around the receipt of findings to be changed over time. This consent process will need to be adapted to the research-to-clinical relationship that unfurls in the circumstances of a clinically relevant SF.
